» Articles » PMID: 33837830

Gluten-degrading Bacteria: Availability and Applications

Overview
Date 2021 Apr 10
PMID 33837830
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Gluten is a mixture of storage proteins in wheat and occurs in smaller amounts in other cereal grains. It provides favorable structure to bakery products but unfortunately causes disease conditions with increasing prevalence. In the human gastrointestinal tract, gluten is cleaved into proline and gluten rich peptides that are not degraded further. These peptides trigger immune responses that might lead to celiac disease, wheat allergy, and non-celiac gluten sensitivity. The main treatment option is a gluten-free diet. Alternatively, using enzymes or microorganisms with gluten-degrading properties might alleviate the disease. These components can be used during food production or could be introduced into the digestive tract as food supplements. In addition, natural food from the environment is known to enrich the microbial communities in gut and natural environmental microbial communities have high potential to degrade gluten. It remains to be investigated if food and environment-induced changes in the gut microbiome could contribute to the triggering of gluten-related diseases. KEY POINTS: • Wheat proteins, gluten, are incompletely digested in human digestive tract leading to gluten intolerance. • The only efficient treatment of gluten intolerance is life-long gluten-free diet. • Environmental bacteria acquired together with food could be source of gluten-degrading bacteria detoxifying undigested gluten peptides.

Citing Articles

Production, Purification, and Biochemical Characterization of a Novel ATP-Dependent Caseinolytic Protease from the Marine Bacterium KMM 296.

Noskova Y, Nedashkovskaya O, Balabanova L Microorganisms. 2025; 13(2).

PMID: 40005674 PMC: 11857851. DOI: 10.3390/microorganisms13020307.


Coeliac Disease in Children-A Clinical Review Including Novel Treatment Agents.

Corlett C, Rodrigues A, Ravikumara M Medicina (Kaunas). 2024; 60(10).

PMID: 39459437 PMC: 11509383. DOI: 10.3390/medicina60101650.


The link between gluten intake and the risk of cancers.

Bakhtiari S, Asri N, Maleki S, Rahimi S, Jabbari A, Ahmadzadeh A Gastroenterol Hepatol Bed Bench. 2024; 17(2):132-139.

PMID: 38994510 PMC: 11234494. DOI: 10.22037/ghfbb.v17i2.2945.


Novel probiotic preparation with gluten-degrading activity and potential modulatory effects on the gut microbiota.

Nikoloudaki O, Celano G, Polo A, Cappello C, Granehall L, Costantini A Microbiol Spectr. 2024; 12(7):e0352423.

PMID: 38860826 PMC: 11218521. DOI: 10.1128/spectrum.03524-23.


From an understanding of etiopathogenesis to novel therapies-what is new in the treatment of celiac disease?.

Skoracka K, Hryhorowicz S, Tovoli F, Raiteri A, Rychter A, Slomski R Front Pharmacol. 2024; 15:1378172.

PMID: 38698821 PMC: 11063403. DOI: 10.3389/fphar.2024.1378172.


References
1.
Lim P, Tan L, Ow D, Wong F . A propeptide toolbox for secretion optimization of Flavobacterium meningosepticum endopeptidase in Lactococcus lactis. Microb Cell Fact. 2017; 16(1):221. PMC: 5715515. DOI: 10.1186/s12934-017-0836-0. View

2.
Medina M, Palma G, Ribes-Koninckx C, Calabuig M, Sanz Y . Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J Inflamm (Lond). 2008; 5:19. PMC: 2640389. DOI: 10.1186/1476-9255-5-19. View

3.
Kocadag Kocazorbaz E, Zihnioglu F . Purification, characterization and the use of recombinant prolyl oligopeptidase from Myxococcus xanthus for gluten hydrolysis. Protein Expr Purif. 2016; 129:101-107. DOI: 10.1016/j.pep.2016.09.016. View

4.
Lagier J, Khelaifia S, Alou M, Ndongo S, Dione N, Hugon P . Culture of previously uncultured members of the human gut microbiota by culturomics. Nat Microbiol. 2016; 1:16203. DOI: 10.1038/nmicrobiol.2016.203. View

5.
Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S . The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010; 42(8):587-95. DOI: 10.3109/07853890.2010.505931. View